Skip to main content

Table 4 Factors associated with abdominal obesity

From: HIV infection, and overweight and hypertension: a cross-sectional study of HIV-infected adults in Western Kenya

 

N

n

%

OR

95% CI

P value

aOR

95% CI

P value

Age category

 18–29

33

16

48.5

1.00

   

1.00

   

 30–39

104

50

48.1

0.98

0.44

2.15

0.967

1.30

0.53

3.19

0.558

 40 and older

114

47

41.2

0.74

0.34

1.66

0.459

1.06

0.44

22.54

0.896

Sex

 Male

82

8

9.8

1.00

   

1.00

   

 Female

169

105

62.1

15.17

6.86

33.53

< 0.0001

15.28

6.84

34.12

< 0.0001

Marital status

 Single

7

3

42.9

1

   

1

   

 Married

154

71

46.1

1.14

0.24

5.26

0.866

1.94

0.35

10.57

0.441

 Divorced

10

4

40.0

0.88

0.12

6.31

0.906

2.11

0.21

20.42

0.516

 Widowed

80

35

43.8

1.03

0.21

4.93

0.963

2.18

0.37

12.68

0.382

Education level

 Low education

96

41

42.7

1.00

   

1.00

   

 Complete primary

117

51

43.6

1.03

0.60

1.78

0.897

0.86

0.45

1.67

0.676

 Complete secondary or higher

38

21

55.3

1.65

0.77

3.53

0.19

1.34

0.50

3.61

0.551

Occupation

 At home

31

15

48.4

1.00

   

1.00

   

 Working outside

48

23

47.9

0.98

0.39

2.42

0.967

0.79

0.26

2.40

0.685

 Working inside

136

57

41.9

0.76

0.35

1.68

0.511

0.63

0.24

1.67

0.360

 Others

36

18

50.0

1.06

0.40

2.78

0.895

0.57

0.17

1.85

0.357

SES

 Poorest

63

23

36.5

1.00

   

1.00

   

 Poor

62

23

37.1

1.02

0.49

2.12

0.945

0.99

0.43

2.28

0.990

 Less poor

62

32

51.6

1.85

0.90

3.79

0.090

1.54

0.68

3.51

0.294

 Rich

63

35

55.6

2.17

1.06

4.44

0.033

1.99

0.86

4.60

0.104

Physical activity level

 Inactive

11

6

54.5

1.00

       

 Minimally active

22

9

40.9

0.57

0.13

2.48

0.46

0.40

0.07

2.28

0.302

 HEPA active

215

97

45.1

0.68

0.20

2.31

0.542

0.55

0.12

2.40

0.429

Chai per day

 0–1 cup

20

8

40.0

1.00

   

1.00

   

 2 cups

58

27

46.6

1.30

0.46

3.66

0.611

1.14

0.32

4.05

0.836

 3 cups or more

173

78

45.1

1.23

0.47

3.16

0.665

0.87

0.27

2.79

0.827

Soda per week

 None

126

58

46.0

1.00

   

1.00

   

 Once

64

27

42.2

0.85

0.46

1.57

0.614

0.66

0.32

1.34

0.255

 Twice or more

61

28

45.9

0.99

0.53

1.83

0.986

0.96

0.46

2.03

0.933

Ugali per day

 Quarter a plate

185

91

49.2

1.00

   

1.00

   

 Half a plate

55

19

34.5

0.54

0.29

1.01

0.057

0.60

0.28

1.27

0.186

 3 quarters a plate or more

8

2

25.0

0.34

0.06

1.75

0.198

0.36

0.04

1.27

0.205

Alcohol

 No

223

103

46.2

1.00

   

1.00

   

 Yes

24

8

33.3

0.58

0.23

1.41

0.233

1.16

0.38

3.52

0.792

Smoke

 No

242

112

46.3

1.00

   

1.00

   

 Yes

9

1

11.1

0.14

0.01

1.17

0.07

0.52

0.04

5.54

0.590

Abdominal obesity

 No

209

92

44.0

1.00

   

1.00

   

 Yes

42

21

50.0

1.27

0.65

2.46

0.477

0.95

0.44

2.09

0.900

Hypertension

 No

222

97

43.7

1.00

   

1.00

   

 Yes

28

16

57.1

1.71

0.77

3.80

0.181

1.72

0.65

4.53

0.272

ART duration

 0–364 days

14

9

64.3

1.00

   

1.00

   

 365 days and more

237

104

43.9

0.43

0.14

1.33

0.145

0.34

0.08

1.39

0.136

CD4 counts (cells/μl)

 < 200

30

15

50.0

1.00

   

1.00

   

 200–499

113

50

44.2

0.79

0.35

1.77

0.574

1.04

0.41

2.65

0.927

 ≥ 500

106

48

45.3

0.82

0.36

1.86

0.647

1.07

0.41

2.75

0.885

On PI

 No

214

95

44.4

1.00

   

1.00

   

 Yes

36

18

50.0

1.25

0.61

2.53

0.532

1.82

0.74

4.44

0.187

PI duration

 0–359 days

7

3

42.9

1.00

   

1.00

   

 540 days and more

28

15

53.6

1.53

0.28

8.18

0.613

0.04

0.00

2.60

0.131

WHO stage

 1

51

20

39.2

1.00

   

1.00

   

 2

71

37

52.1

1.68

0.81

3.50

0.160

2.37

0.97

5.73

0.056

 3

97

40

41.2

1.08

0.54

2.17

0.811

1.14

0.51

2.58

0.736

 4

29

15

51.7

1.66

0.66

4.16

0.279

1.85

0.61

5.57

0.269

OI history

 No

204

88

43.1

1.00

   

1.000

   

 Yes

45

24

53.3

1.50

0.78

2.87

0.215

2.21

0.97

5.02

0.057

  1. N number of study participants, n number of elements in a sample, OR odds ratio, 95% CI 95% confidential interval, aOR adjusted odds ratio, P value probability value, HEPA health-enhancing physical activity, ART anti-retroviral therapy, PI protease inhibitor, WHO stage WHO clinical staging of HIV/AIDS for adults and adolescents, OI opportunistic infection